In patients with CCA with FGFR2 fusion/rearrangement naïve for FGFR inhibitors, the ORR was 52% (13/25), and in those treated at the recommended dose for the phase II study, the ORR was 100% (4/4). Here, FGFR2 is linked to cholangiocarcinoma.